1. [1] Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, e al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-An update on the status. Mil Med Res 2020; 7: 11-20 [ DOI:10.1186/s40779-020-00240-0] [ PMID] [ PMCID] 2. [2] Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis: Observations and hypotheses. Lancet 2020; 395: 1517-1520. [ DOI:10.1016/S0140-6736(20)30920-X] 3. [3] Mishra A, Kaur U, Singh A. Fisetin 8-C-glucoside as entry inhibitor in SARS CoV-2 infection: molecular modelling study. J Biomol Struct Dyn 2020; 1-10. [ DOI:10.1080/07391102.2020.1868335] [ PMID] [ PMCID] 4. [4] Santana FP, Thevenard F, Gomes KS, Taguchi L, Câmara NO, Stilhano RS, et al. New perspectives on natural flavonoids on COVID‐19‐induced lung injuries. Phytother Res 2021; 35: 4988-5006. [ DOI:10.1002/ptr.7131] [ PMID] [ PMCID] 5. [5] Astuti I. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. diabetes and metabolic syndrome. Clin Res Rev 2020; 14: 407-412. [ DOI:10.1016/j.dsx.2020.04.020] [ PMID] [ PMCID] 6. [6] Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367: 1444-1448. [ DOI:10.1126/science.abb2762] [ PMID] [ PMCID] 7. [7] Burgos-Blasco B, Güemes-Villahoz N, Santiago JL, Fernandez-Vigo JI, Espino-Paisán L, Sarriá B. Hypercytokinemia in COVID-19: Tear cytokine profile in hospitalized COVID-19 patients. Exp Eye Res 2020; 200: 108253-108258. [ DOI:10.1016/j.exer.2020.108253] [ PMID] [ PMCID] 8. [8] Báez-Santos YM, John SE, Mesecar AD. The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds. Antiviral Res 2015; 115: 21-38. [ DOI:10.1016/j.antiviral.2014.12.015] [ PMID] [ PMCID] 9. [9] Jucá MM, Cysne Filho FM, de Almeida JC, Mesquita DD, Barriga JR, Dias KC, et al. Flavonoids: Biological activities and therapeutic potential. Nat Prod Res 2020; 34: 692-705. [ DOI:10.1080/14786419.2018.1493588] [ PMID] 10. [10] Camell CD, Yousefzadeh MJ, Zhu Y, Prata LG, Huggins MA, Pierson M, et al. Senolytics reduce coronavirus-related mortality in old mice. Science 2021; 373: eabe4832. [ DOI:10.1126/science.abe4832] [ PMID] [ PMCID] 11. [11] Crane MJ, Devine S, Jamieson AM. Graphene oxide/silver nanoparticle ink formulations rapidly inhibit influenza A virus and OC43 coronavirus infection in vitro. Bio Rxiv 2021. [ DOI:10.1101/2021.02.25.432893] 12. [12] Zhao Z, Xiao Y, Xu L, Liu Y, Jiang G, Wang W, et al. Glycyrrhizic acid nanoparticles as antiviral and anti-inflammatory agents for COVID-19 treatment. ACS Appl Mater Interfaces 2021; 13: 20995-21006. [ DOI:10.1021/acsami.1c02755] [ PMID] [ PMCID] 13. [13] Dourado D, Freire DT, Pereira DT, Amaral-Machado L, Alencar ÉN, de Barros AL, Egito ES. Will curcumin nanosystems be the next promising antiviral alternatives in COVID-19 treatment trials. Biomed Pharmacother 2021; 139: 111578. [ DOI:10.1016/j.biopha.2021.111578] [ PMID] [ PMCID] 14. [14] Neghab HK, Azadeh SS, Soheilifar MH, Dashtestani F. Nanoformulation-Based antiviral combination therapy for treatment of COVID-19. Avicenna J Med Biotechnol 2020; 12: 255-256.
|